« Previous | Next » | All Messages |  CMPD Message Board Home | recommend post |  Ignore Poster

CMPD News CompuMed Recruits Medical Imaging Veteran for Top Sales Post

LOS ANGELES--(BUSINESS WIRE)--CompuMed, Inc. (OTCBB:CMPD) – a medical informatics company leading the development of advanced imaging technology for cost-effective analysis and monitoring – today announced the appointment of Manning H. Phillips as the company’s new Director of Sales and Marketing.

“We are very pleased to have Manning on board to drive CompuMed’s sales and business development growth,” said CompuMed CEO Jerry McLaughlin. “Manning’s strong track record in both domestic and international medical imaging markets will prove valuable as he spearheads our expansion initiatives and manages our field OEM relationships.”

In his new post, Mr. Phillips will be responsible for CompuMed’s global sales efforts, with a focus on the company’s OsteoGram products for screening, diagnosing and monitoring osteoporosis. He joins CompuMed with more than 16 years of experience in the digital medical imaging field. Most recently, he served as business development manager of radiology and telemedicine markets for VIDAR SYSTEMS CORPORATION (Herndon, VA), the leading manufacturer of medical film scanners for PACS, Teleradiology, CAD and Oncology markets. While at VIDAR, he was responsible for more than 400% growth in the North American and Asia Pacific markets, where he managed OEM and integrator sales. Prior to his tenure at VIDAR, Mr. Philips held positions of increasing responsibility with EMED, the PACS Division of Raytheon; Polaroid Medical Systems; and GE Medical Systems. He earned a B.S. in engineering from California Polytechnic, San Luis Obispo, and an executive MBA from the University of New Hampshire, Durham.

About CompuMed:

Founded in 1973, CompuMed, Inc. (OTCBB:CMPD) is leading the development of advanced imaging and medical informatics solutions that provide cost-effective analysis and monitoring. CompuMed focuses on cardiovascular and musculoskeletal diseases, as well as other diseases associated with aging populations. Its unique expertise in telemonitoring, imaging and analysis facilitates the development of new solutions and services designed to improve healthcare provider workflow and patient care, while reducing costs. CompuMed's core products, the OsteoGram^® and CardioGram^TM systems, are cleared by the FDA and reimbursable by Medicare. The OsteoGram is an accurate and precise technology for osteoporosis testing. The underlying OsteoGram technology has significant cost advantages over other technologies and will be applied to a suite of value-added applications, such as following the progression of arthritic disease and diagnosing vertebral fractures and scoliosis. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms, and is used by private practice as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within two minutes of receipt, and has the additional capability of automatically providing an over-read (i.e., follow- up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net.

This news release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks, including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, availability of appropriate acquisition candidates and/or business partnerships, economic conditions, impact of competition and pricing, capacity and supply constraints or difficulties, government regulation, and other risks disclosed from time to time in our filings with the Securities and Exchange Commission. All such forward-looking statements, whether made by or on behalf of the Company, are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.